TCRX קפיטליזציה חשבונאית TScan Therapeutics, Inc.
The price chart for TScan Therapeutics (TCRX) on the GURU.Markets platform is currently at 0.07. The business relies on scientific alliances to develop personalized immune treatments. TScan Therapeutics (TCRX) implements ESG principles, strictly adhering to biosafety and research ethics. Operations in the solid tumor therapy segment are supported by stable funding, although growth rates are limited by stringent FDA oversight of gene editing.
פילוחי מדדים פיננסיים ומדדי שוק עבור TScan (TCRX)
High R&D expenditures associated with T-cell therapy clinical trials define the specific financial profile of TScan Therapeutics (TCRX) during its pre-profit stage. By analyzing book capitalization trends, investors assess the value of net assets minus liabilities, which allows for the monitoring of capital preservation and bankruptcy risk despite the absence of current operating profit.